NCM · Medical - Devices

electroCore, Inc. (ECOR) Stock

$6.02 -2.75% NCM: ECOR Healthcare

electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies.

Valuation

MetricValue
Price$6.02
Market Cap$49.94M
P/E Ratio-3.42
P/B Ratio-9.74
P/S Ratio1.47
EPS (TTM)$-1.65
52-Week High$10.49
52-Week Low$4.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE836.32%
ROA-99.35%
ROCE-462.20%
Gross Margin-40.62%
Operating Margin-40.62%
Net Margin-44.08%
Debt/Equity-1.67
Current Ratio1.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$5.0M$9.0M$16.0M$25.0M$32.0M
Operating Profit$-20.0M$-23.0M$-19.0M$-12.0M$-13.0M
Net Profit$-17.0M$-22.0M$-19.0M$-12.0M$-14.0M
EPS$-4.36$-4.69$-3.42$-1.59$-1.65
Op Margin-367.7%-266.2%-117.3%-48.3%-41.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$25.0M$16.0M$20.0M$19.0M
Total Liabilities$6.0M$8.0M$9.0M$13.0M$20.0M
Cash$35.0M$18.0M$10.0M$3.0M$7.0M
Borrowings$1.0M$1.0M$1.0M$4.0M$9.0M

Latest News

New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation GlobeNewswire · Jul 16, 2026 iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today ACCESS Newswire · Jun 23, 2026 iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026 ACCESS Newswire · Jun 18, 2026 electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference GlobeNewswire · Jun 17, 2026 Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery GlobeNewswire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-17.0M$-15.0M$-7.0M$-8.0M
Investing Cash Flow$18.0M$0$0$-9.0M$4.0M
Financing Cash Flow$0$0$-1.0M$0$0
Net Cash Flow$30.0M$-17.0M$-7.0M$-7.0M$3.0M
Free Cash Flow$-14.0M$-17.0M$-15.0M$-7.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.26
EV / EBITDA-4.22
FCF Yield-16.02%
Quick Ratio0.91
Interest Coverage-13.00
Return 1Y-13.38%
Return 3Y32.02%
Return 5Y-60.65%

Ownership

Insiders Held33.33%
Institutions Held8.44%
Institutions Float Held12.66%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC202,6442026-03-31
Balyasny Asset Management LP116,4632026-03-31
Geode Capital Management, LLC78,0832026-03-31
Jaffetilchin Investment Partners, LLC58,1982026-03-31
Wealthspire Advisors, LLC47,4982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About electroCore, Inc.

electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.

electroCore, Inc. is led by CEO Thomas J. Errico, employs 73 people, headquartered in US, publicly traded since 2018.

electroCore, Inc. (ECOR) stock trades at $6.02 with a market capitalization of $49.94M. The stock is valued at a price-to-earnings (P/E) ratio of -3.42, price-to-book of -9.74, price-to-sales of 1.47. Over the past 52 weeks the stock has ranged between $4.16 and $10.49, and currently trades 42.6% below its 52-week high.

On profitability, electroCore, Inc. generates a return on equity (ROE) of 836.32% — well above the market average, a sign of a high-quality business, return on capital employed of -462.20%, an operating margin of -40.62%, a net profit margin of -44.08%.

Official website: www.electrocore.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides